Levobupivacaïne Molteni (Levobupivacaine)

Levobupivacaine blocks voltage‑gated sodium channels on peripheral nerve membranes, preventing the influx of sodium ions required for action potential generation. This reversible inhibition stabilises the neuronal membrane, halting the propagation of nerve signals and resulting in loss of sensation and, at higher concentrations, motor block in the treated area.

The specific dose of Levobupivacaïne Molteni is determined by the prescribing clinician based on the patient’s age, weight, the type of procedure, and the intended route of administration (epidural, infiltration or intrathecal). Dosage guidelines are provided in the product’s prescribing information and must be followed by qualified healthcare professionals.

Safety data for levobupivacaine in pregnancy and lactation are limited. The drug may be used when the potential benefit justifies the potential risk to the fetus, typically in obstetric analgesia under close supervision. It is excreted in small amounts in breast milk, so breastfeeding mothers should consult their obstetrician or anesthesiologist before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and assistance with import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of action with a lower risk of cardiotoxicity and central nervous system toxicity. Both provide long‑lasting anesthesia, but levobupivacaine is often preferred when a safer cardiac profile is desired, especially in high‑risk patients.

The product should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the solution. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique when preparing for injection.

Levobupivacaïne Molteni is supplied as a sterile solution for injection. It can be administered epidurally, intrathecally or by direct infiltration into tissues, depending on the clinical indication. Administration must be performed by a qualified healthcare professional using appropriate aseptic technique and dosage calculations.

Serious risks include cardiovascular toxicity such as arrhythmias, hypotension, or cardiac arrest, and central nervous system toxicity manifesting as seizures, respiratory depression or loss of consciousness. Rarely, allergic reactions or methemoglobinemia may occur. Immediate medical intervention is required if any of these signs develop.

Patients with a known hypersensitivity to levobupivacaine or any amide‑type local anesthetic should avoid the product. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those receiving other agents that significantly increase the risk of local anesthetic systemic toxicity.